HSBC Holdings
LCTX icon

HSBC Holdings’s Lineage Cell Therapeutics LCTX Stock Holding History

HSBC Holdings’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-72,248
Closed -$66K – 2957
2025
Q2 		$66K Buy
72,248
+51,288
+245% +$30.4K ﹤0.01% 2909
2025
Q1 		$9.84K Buy
20,960
+3,572
+21% +$2.1K ﹤0.01% 2985
2024
Q4 		$8.75K Sell
17,388
-300
-2% -$220 ﹤0.01% 3073
2024
Q3 		$16.1K Buy
17,688
+2,696
+18% +$2.5K ﹤0.01% 2955
2024
Q2 		$14.5K Sell
14,992
-226
-1% -$250 ﹤0.01% 2885
2024
Q1 		$22.5K Buy
+15,218
New +$17.3K ﹤0.01% 2987
2017
Q1 		– Sell
-13,670
Closed -$43K – 2369
2016
Q4 		$43K Buy
+13,670
New +$42K ﹤0.01% 2675

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

HSBC Holdings's LCTX Position: Q3 2025 in Review

HSBC Holdings sold out of Lineage Cell Therapeutics (LCTX) in Q3 2025, closing a stake of 72,248 shares — an estimated $66K sold.

HSBC Holdings first reported a position in LCTX in Q4 2016 and held it in 7 quarters. The position peaked at $66K in Q2 2025. 112 funds tracked by Wall St. Rank hold LCTX as of Q3 2025.

  • HSBC Holdings reported no remaining Lineage Cell Therapeutics position as of Q3 2025 after selling out during the quarter.
  • HSBC Holdings sold 72,248 Lineage Cell Therapeutics shares in Q3 2025, an estimated $66K.
  • HSBC Holdings first reported a position in Lineage Cell Therapeutics in Q4 2016 and held it in 7 quarters.
  • HSBC Holdings's Lineage Cell Therapeutics position peaked at $66K in Q2 2025.
  • 112 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2025.

Based on HSBC Holdings's 13F filing for Q3 2025, filed 13 Nov 2025.